Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide, accounting for more than 1 million deaths per year. 1 Adenocarcinoma is the most common histological subtype of NSCLC, comprising almost half of all lung submit your manuscript | www.dovepress.com
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sun et al cancers. 2 During the last few years, with the improvement in the knowledge of lung cancer biology, molecular and clinical characteristics, the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS) integrated the clinical, radiological, molecular, and pathologic approaches to classify various types of lung adenocarcinoma. The new IASLC/ATS/ERS classification established histological categories with prognostic differences to identify the candidates for adjunctive therapy after/before surgery. 2 The goal of the new classification of lung adenocarcinoma is to provide accurate diagnosis and obtain predictive and prognostic data for the patients' outcomes. The stronger association with long-term survival for the IASLC/ ATS/ERS classification has affect on TNM staging of early-stage lung adenocarcinomas. In addition, several gene expression-based signatures predicting survival with the use of microarrays or polymerase chain reaction (PCR) have also been demonstrated to predict the prognosis of patients with lung cancer accurately after resection of early-stage NSCLC. [3] [4] [5] Kratz et al 3 developed a practical gene signature for early-stage lung nonsquamous carcinoma that improved risk stratification compared with conventional staging; our research team participated in the multicenter validation in this study. In this gene set, BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, and SH3BGR, which are intricately related to lung cancer proliferation, are known elements of classical oncogenic molecular pathways (Table 1) . This gene expression-based signature can better predict survival and disease recurrence compared to clinical stage among early-stage adenocarcinoma patients, but the predictive power of this prognostic gene signature has never been evaluated in the circumstances of the IASLC/ATS/ERS classification.
In this study, we investigated the relationship between this gene set and the histological categories according to the IASLC/ ATS/ERS classification, and we tried to clarify whether the gene signature is a suitable molecular biomarker to provide improved risk stratification by the IASLC/ATS/ERS classification criteria in patients with early-stage lung adenocarcinoma.
Patients and methods Patients
The human sample collection procedure was approved by the ethical committee of the Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai Pulmonary Hospital, Shanghai Tongji University, Shanghai Huadong Hospital, and Shanghai Fudan University. Between April 2002 and April 2007, 2,696 patients underwent surgical lobectomy of NSCLC TNM staging was unified according to the seventh edition of the IASLC's system for NSCLC before being subjected to subsequent statistical analysis. 6 
IASLC/ATS/ERS classification of lung adenocarcinoma and grouping methods
The new classification strategy of lung adenocarcinoma is based on the criteria proposed by the IASLC, ATS, and ERS in 2011. 2 Four subtypes were included: adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma (IA, including the subtypes of lepidic predominant, acinar predominant, papillary predominant, micropapillary predominant, and solid predominant), and variants of IA (including the subtypes of invasive mucinous adenocarcinoma, colloid, fetal, and enteric). Two pathologists (L Hou and H Xie) assessed all hematoxylin and eosin-stained slides independently.
According to the prognosis of survival of the IASLC/ ATS/ERS classification subtypes reported by Yoshizawa et al 7 and Van Schil et al, 8 the selected 93 patients were assigned to three groups: low, intermediate, and high grade ( Table 2) .
Total rna extraction and real-time Pcr quantification of the selected gene
To identify the correlation between gene expressions and the clinical outcome, we analyzed the expression of eleven genes, BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and YAP1, in 105 surgical specimens using real-time PCR.
For RNA extraction from the formalin-fixed, paraffinembedded samples, we used kits (MasterPure RNA Purification Kit; Epicentre Biotechnologies, Madison, WI, USA) and followed the manual's instruction. Reverse transcription was done for the extracted RNA with gene-specific priming (iScript Select cDNA Synthesis Kit; Bio-Rad Laboratories Inc., Hercules, CA, USA) followed by cDNA preamplification (TaqMan PreAmp Master Mix; Thermo Fisher Scientific, Waltham, MA, USA). Taqman real-time PCR was performed for cDNA in 384-well plates using Prism the 7900HT machine (Thermo Fisher Scientific). Quantitative PCR was performed for each sample in triplicate. The 
statistical analysis
The data were expressed as median and interquartile range. A nonparametric Wilcoxon Mann-Whitney U-test was used to calculate the difference between the gene expression of two groups, and Kruskal-Wallis H test was used for several independent samples. A chi-square test was used to compare proportional data.
The risk score of the ten-gene signatures (RS10) for each patient was calculated as a linear combination of the -ΔΔCt of BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, and SH3BGR with the same weights, as described by Kratz et al 3 (RS10 =39.39747*(0.00237*BAG1 +0.14607* BRCA1 +0.08335*CDC6 +0.18653*CDK2AP1 -0.06638* ERBB +0.03458*FUT3 +0.01383*IL11 -0.20988*LCK + 0.08849*RND3 -0.19821*SH3BGR) -16.94965+1). The resulting predicted risk scores were dichotomized (at the median), and the corresponding Kaplan-Meier survival Figure 1A ). The IASLC/ ATS/ERS classification with a c-index of 0.704 was better in discriminating patients' prognosis, compared to TNM staging with a c-index of 0.640 (Table 4 ; Figure 1B and C). The ten-gene risk score was also related to prognosis with a c-index of 0.587. The median survival time was 81.0 months for the lower risk score (95% CI: 67.2-94.8), while it was 51.0 months (95% CI: 38.2-63.8) for the higher risk score, which is significantly longer compared to the group with the lower risk score (P,0.001) ( Table 4 ; Figure 1D ).
The ten-gene signature does not predict survival of early-stage pulmonary adenocarcinoma independently of the IASLC/ATS/ERS classification.
To clarify the interaction between the ten-gene risk score and TNM staging or IASLC/ATS/ERS classification in survival prediction, the hazard ratio of the ten-gene risk score was adjusted in the TNM-based or IASLC/ATS/ERS classification-based models using multivariable Cox regression (Table 5 ). The ten-gene risk score is still an independent prognostic factor after adjusting for TNM staging, suggesting that the ten-gene risk score can improve the discriminatory value of TNM staging in survival prediction. However, the hazard ratio of the ten-gene risk score was not statistically significant after adjusting for the IASLC/ATS/ERS classification, which implies the collinearity of predictive variables between the ten-gene risk score and the IASLC/ATS/ERS classification.
Two-gene signature containing BRCA1 and ERBB3 can improve the discriminatory value of prognostic prediction of IASLC/ATS/ERS classification in early-stage lung adenocarcinoma.
Because the algorithm of the ten-gene signature may not be optimal for the IASLC/ATS/ERS classification, we reanalyzed the association of survival with the expression levels 
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Molecular biomarker of IASLC/ATS/ERS classification of the ten genes separately, adjusting for the IASLC/ATS/ ERS classification using the Cox regression. The expression levels of BRCA1 and ERBB3 emerged as independent predictive factors of survival after adjusting for the IASLC/ ATS/ERS classification (Table 6 ). Therefore, we developed a new algorithm of two-gene signature containing BRCA1 and ERBB3, namely, the risk score of the two-gene signature (RS2) =0.475*BRCA1 +0.048*ERBB3, to improve the discriminatory value of prognosis prediction of the IASLC/ ATS/ERS classification. RS2 was calculated for each patient, and it was dichotomized at the median of 4.98.
To evaluate the improvement of the prognostic value by the risk score of the two-gene signature consisting of BRCA1 and ERBB3, the discriminatory power of the predictive models of the TNM stage or IASLC/ATS/ERS classification with risk score was evaluated using c-statistics or areas under the receiver operating characteristic curve. The TNM stage alone achieved a discriminatory c-statistic of 0.640 (Table 4) . Adding the clinical parameters only slightly improved the discriminatory value to 0.685 (Table 7) . The IASLC/ATS/ ERS classification alone achieved a c-statistic of 0.704 (Table 4) , and adding the clinical parameters improved the c-statistic to 0.728 (Table 7) . Adding the risk score of the two-gene signature to the IASLC/ATS/ERS classification model further improved the discriminatory c-statistic to 0.756, which gave the best performance of the predictive model (Table 7) .
Overall, the prognostic value of the risk score of the two-gene signature improved the IASLC/ATS/ERS classification for assessing the prognosis of early-stage lung adenocarcinoma. The time-dependent area under the curve plot of the model based on the IASLC/ATS/ERS classification and improved model based on risk score confirmed that the risk score of the two-gene signature together with IASLC/ ATS/ERS classification showed a better overall discriminatory ability over time compared to the IASLC/ATS/ERS classification alone (Figure 2 ).
Discussion
The novel IASLC/ATS/ERS classification of lung adenocarcinoma has markedly promoted the pathologic diagnosis of lung cancer. The new criteria introduce a new concept of early-stage lung cancer consisting of AIS and MIA and categorize IAs by the predominant histological pattern. Importantly, the IASLC/ATS/ERS classification serves as a rapid and efficient discriminator of patient prognosis, and it can support patient stratification for adjuvant chemoradiotherapy or targeted therapy after surgery. 9 Several gene expression-based signatures were also believed to be useful in identifying the candidates for adjunctive therapy after/before surgery. Although some gene signatures were believed to predict survival better compared to traditional TNM classification, whether these gene signatures are independent of the IASLC/ATS/ERS classification has seldom been evaluated. In this study, we proposed that a two-gene signature composed of BRCA1 and ERBB3 was a risk factor independent of the IASLC/ATS/ERS classification, which would improve the discriminatory power of prognosis prediction for IASLC/ATS/ERS classification. BRCA1 (breast cancer 1, early onset) is a tumor suppressor gene involved in the repair of chromosomal damage with an important role in the errorfree repair of DNA double-strand breaks. 10 Germline mutations of BRCA1 have been associated with an increased risk of breast, ovarian, and prostate cancer. 11 The overexpression of BRCA1 mRNA was strongly associated with poor survival in NSCLC patients. 12, 13 The ERBB3 gene encodes a member of the epidermal growth factor receptor family of receptor tyrosine kinases. The overexpression of ERBB3 (HER3) has been reported both in primary cancers and in cultured cells, including the carcinomas of lung, breast, ovarian, prostate, Abbreviations: aTs, american Thoracic society; aUc, area under the curve; ers, european respiratory society; iaslc, international association for the study of lung cancer; rs2, risk score of two-gene signature.
colon, pancreas, stomach, and oral cavity, 14, 15 and it has been shown that ERBB3 (HER3)'s overexpression was associated with worse OS at both 3-and 5-year period. 16 We verified that the ten-gene signature was an independent prognostic factor in the TNM-based system, but not in the IASLC/ATS/ OncoTargets and Therapy 2016:9 submit your manuscript | www.dovepress.com
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sun et al ERS classification model. Based on the novel IASLC/ATS/ ERS scheme, the adjusted model with two-gene signatures showed improved discriminatory power in patient prognostic models in early-stage lung adenocarcinoma.
As a heterogeneous disease, NSCLC will have different statistical outcomes even for patients with similar clinical and pathological features. The prognosis of surgically treated lung adenocarcinoma differed significantly across different subtypes. The survival rate of surgically treated AIS is 100% and MIA is near 100%. Lepidic predominant adenocarcinomas have a 5-year survival rate of 90%. Acinar and papillary predominant adenocarcinomas have a 5-year survival rate of 85%-85.5%. 7, 17 In addition, micropapillary predominant adenocarcinomas have a 5-year survival rate of only 67% in a series of stage I adenocarcinomas, and solid adenocarcinoma with mucin components has a 5-year survival rate of only 34.6%. 7 Based on the prognostic value of the subtype of this new classification, early-stage lung adenocarcinoma was divided into low-, intermediate-, and high-grade groups. 7, 8 Our findings revealed similar results to those reported previously, with 5-year survival rates of 100%, 77.6%, and 26.9% for the three groups, respectively. Because AIS and MIA types are curable with a complete resection, they may provide a selection for surgeons considering limited resection over standard lobectomy and mediastinal lymph node dissection as treatment options. Therefore, it is important to recognize different subtypes of the IASLC/ATS/ERS classification in early-stage lung adenocarcinomas.
Several previous clinical trials have documented that stage I NSCLC patients did not gain a statistically clinical benefit from adjuvant chemotherapy. 18, 19 The current therapy for stage I NSCLC patients is surgical resection without adjuvant chemotherapy. The evidence suggests that the IASLC/ ATS/ERS classification is able to identify patients in the high-risk group with very poor long-term survival, such as those subtypes with micropapillary and solid predominant lung adenocarcinoma. Subsets with a poor prognosis could be selected for inclusion in clinical trial testing for additional therapeutic agents. We found that the two-gene signature provided better prognostic stratification compared to the IASLC/ATS/ERS classification alone. Thus, we believe two-gene signatures combined with the new classification system could help identify stage I lung adenocarcinoma patients at a high risk for recurrence who may benefit from adjuvant chemotherapy or novel treatment approaches. This prognostic tool would improve their OS rate.
